| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0002-9378(85)90567-8 |
| P698 | PubMed publication ID | 3927737 |
| P2093 | author name string | Whitehead MI | |
| Padwick ML | |||
| Endacott J | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1085-1091 | |
| P577 | publication date | 1985-08-01 | |
| P1433 | published in | American Journal of Obstetrics and Gynecology | Q4744256 |
| P1476 | title | Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women | |
| P478 | volume | 152 |
| Q37070505 | 9 Oestrogen therapy and cardiovascular disease: Do the benefits outweigh the risks? |
| Q34114548 | A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). |
| Q39431911 | A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women |
| Q38219866 | A review of contact dermatitis associated with transdermal therapeutic systems |
| Q37974171 | A risk-benefit assessment of estrogen therapy in postmenopausal women |
| Q34214188 | Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms. |
| Q39314837 | An Australian experience of transdermal oestradiol patches in a subtropical climate |
| Q39532658 | Comparison of gel and patch estradiol replacement in Brazil, a tropical country |
| Q43490648 | Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women |
| Q53979884 | Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. |
| Q53979881 | Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability. |
| Q69948918 | Contact dermatitis to transdermal estradiol system |
| Q39513315 | Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment |
| Q70326970 | Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women |
| Q70335551 | Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women |
| Q70344111 | Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women |
| Q36033417 | Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women |
| Q67763646 | Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system |
| Q78016942 | Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group |
| Q39432071 | Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints |
| Q73343199 | Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women |
| Q39459580 | Estradiol delivery by vaginal rings: potential for hormone replacement therapy |
| Q39434008 | Estradiol-delivering vaginal rings for hormone replacement therapy |
| Q39608616 | Hercon technology for transdermal delivery of drugs |
| Q39467095 | Hormone replacement therapy in the aged. A state of the art review |
| Q73405849 | Inhibition of ovulation with transdermal estradiol and oral progestogens in perimenopausal women |
| Q73416877 | OESCLIM: summary of tolerability and safety |
| Q35009434 | Optimisation of treatment by applying programmable rate-controlled drug delivery technology |
| Q39495910 | Percutaneous and transdermal oestrogen replacement therapy |
| Q39557766 | Pharmacokinetic considerations in the use of newer transdermal formulations |
| Q35167935 | Prolonged endometrial stimulation associated with oestradiol implants |
| Q53668293 | Quality of life after the menopause: influence of hormonal replacement therapy. |
| Q67575998 | Suppression of ovarian function with the transdermally given synthetic progestin ST 1435 |
| Q44245583 | The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. |
| Q40877130 | The practicalities of hormone replacement therapy |
| Q39489739 | Topical estrogens. Current status |
| Q67812485 | Transdermal absorption of the progestin ST-1435: Therapeutic serum steroid concentrations and high excretion of the steroid in saliva |
| Q23920123 | Transdermal drug delivery: a perspective |
| Q67828146 | Transdermal estradiol substitution therapy for the induction of puberty in female hypogonadism |
| Q37787758 | Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints |
| Q35664612 | Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis |
| Q45076616 | Transdermal estrogen replacement in ovarian failure for ovum donation. |
| Q46188704 | Transdermal oestrogen for postmenopausal women: a double blind crossover comparative study with ethinyl oestradiol |
| Q48898382 | Transdermal oestrogen replacement therapy in a Finnish population |
| Q50946018 | Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women. |
| Q39231571 | Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate |
Search more.